Evidence map›Paper›PMID 35278253›Full record

ArticleClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2022

Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three-month prospective study.

Misbah Noshela Ghazanfar, Ewa Anna Bartko, Nicolai Skovbjerg Arildsen, Lars K Poulsen, Bettina Margrethe Jensen, Christian Enevold, Jesper Grønlund Holm, Anders Woetmann, Niels Ødum, Simon Francis Thomsen

Abstract readLetter
In one paragraph

Article in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three-month prospective study.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Misbah Noshela GhazanfarDepartment of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.ORCID 0000-0003-1475-4121
Ewa Anna BartkoAllergy Clinic, Gentofte Hospital, Copenhagen, Denmark.
Nicolai Skovbjerg ArildsenDepartment of Immunology and Microbiology, LEO Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-1596-3120
Lars K PoulsenAllergy Clinic, Gentofte Hospital, Copenhagen, Denmark.
Bettina Margrethe JensenAllergy Clinic, Gentofte Hospital, Copenhagen, Denmark.
Christian EnevoldInstitute for Inflammation Research, Copenhagen, Denmark.
Jesper Grønlund HolmDepartment of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
Anders WoetmannDepartment of Immunology and Microbiology, LEO Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark.
Niels ØdumDepartment of Immunology and Microbiology, LEO Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark.
Simon Francis ThomsenDepartment of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Allergic AgentsChronic UrticariaUrticariaChronic DiseaseHumansOmalizumabProspective StudiesTreatment OutcomeAnti-Allergic AgentsOmalizumabbody mass indexchronic urticariaIgEomalizumabpharmacokinetics

Identifiers

PMID35278253
PMCPMC9311165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.